Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Long-term treatment with glucagon-like peptide (GLP)-1 or its analog can improve insulin sensitivity. However, continuous administration is required due to its short half-life. We hypothesized that continuous production of therapeutic levels of GLP-1 in vivo by a gene therapy strategy may remit hyperglycemia and maintain prolonged normoglycemia. We produced a recombinant adenovirus expressing GLP-1 (rAd-GLP-1) under the cytomegalovirus promoter, intravenously injected it into diabetic ob/ob mice, and investigated the effect of this treatment on remission of diabetes, as well as the mechanisms involved. rAd-GLP-1–treated diabetic ob/ob mice became normoglycemic 4 days after treatment, remained normoglycemic over 60 days, and had reduced body weight gain. Glucose tolerance tests found that exogenous glucose was cleared normally. rAd-GLP-1–treated diabetic ob/ob mice showed improved β-cell function, evidenced by glucose-responsive insulin release, and increased insulin sensitivity, evidenced by improved insulin tolerance and increased insulin-stimulated glucose uptake in adipocytes. rAd-GLP-1 treatment increased basal levels of insulin receptor substrate (IRS)-1 in the liver and activation of IRS-1 and protein kinase C by insulin in liver and muscle; increased Akt activation was only observed in muscle. rAd-GLP-1 treatment reduced hepatic glucose production and hepatic expression of phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and fatty acid synthase in ob/ob mice. Taken together, these results show that a single administration of rAd-GLP-1 results in the long-term remission of diabetes in ob/ob mice by improving insulin sensitivity through restoration of insulin signaling and reducing hepatic gluconeogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its main roles are the stimulation of insulin release [30], suppression of glucagon secretion [31], delay of gastric emptying and reduction in food intake [32].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [32]
In the citing paper
“Metabolic effects mediated by GLP-1 include increased glucose uptake and glycogen production in skeletal muscle, as well as inhibition of gluconeogenesis in the liver [38]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [38]
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“In type 2 diabetic patients, subcutaneous infusion of GLP-1 for 6 weeks resulted in improved insulin sensitivity and -cell function (6).”
BackgroundResultKohn, A. D., Summers, S. A., Birnbaum, M. J., & Roth, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31372 · Cited by 1,284
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757 · cited 1×
“Elevated hepatic glucose production, due to increased gluconeogenesis, glycogenolysis, or both, is associated with the pathogenesis of type 2 diabetes (38,39).”
Background
Cited by
Items 101–159 of 159
Jurowich, C. F., Otto, C., Rikkala, P. R., Wagner, N., Vrhovac, I., Sabolić, I., Germer, C., & Koepsell, H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490365 · Cited by 15
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13
Amelioration of hyperglycemia by intestinal overexpression of glucagon-like peptide-1 in mice
Liu, M.-J., Han, J., Lee, Y.-S., Park, M.-S., Shin, S., & Jun, H. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0571-z · Cited by 14
Self-citationZhang, G. K. (2011) · Canadian Journal of Surgery · doi:10.1503/cjs.044209 · Cited by 12
Blaslov, K., Bulum, T., Zibar, K., & Duvnjak, L. S. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12194 · Cited by 12
Wang, L., Guo, F., Shi, W., & Zhao, R. (2011) · Peptides · doi:10.1016/j.peptides.2011.03.018 · Cited by 11
Vedantham, S., Kluever, A.-K., & Deindl, E. (2018) · Cells · doi:10.3390/cells7100181 · Cited by 13
Chayati, I., Sunarti, S., Marsono, Y., & Astuti, M. (2019) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-7-4-7 · Cited by 11
Lei, X., Wu, Q., Leng, W., Wu, M., Chen, L., & Liang, Z. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.17 · Cited by 10
Liu, R., Li, Y., Ren-min, H., Jin, T., Deng, S., Wang, L., Zhang, N., Chen, J., Prud’homme, G. J., Jia, W. W.-G., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.131 · Cited by 11
Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice
Riedel, M. J., Lee, C. W. K., & Kieffer, T. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90768.2008 · Cited by 11
Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
Kim, P., & Kim, S. W. (2012) · ISRN Endocrinology · doi:10.5402/2012/340632 · Cited by 9
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
Luo, X., Fang, T., Tan, C. N., Xu, C.-Y., Zheng, Z., Pang, Q., He, X.-A., Cao, J., & Duan, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i39.5471 · Cited by 8
Yanay, O., Moralejo, D. H., Kernan, K. A., Brzezinski, M., Fuller, J. M., Barton, R. W., Lernmark, Å., & Osborne, W. R. A. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1466 · Cited by 8
Rattanaamnuaychai, P., Roshorm, Y. M., Wilasrusmee, C., Proprom, N., Ongphiphadhanakul, B., & Talchai, S. C. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04951 · Cited by 8
Young-Onset Type 2 Diabetes: When Gluconeogenesis Is Overfueled and Out of Control
Alhenc‐Gelas, F., & Marre, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae123 · Cited by 5
Zheng, J.-X., Xiao, Y.-C., Hu, Y., Hao, M., & Kuang, H. (2014) · Andrologia · doi:10.1111/and.12252 · Cited by 9
Levine, J. A., Kaihara, K. A., Layden, B. T., & Wicksteed, B. L. (2016) · Islets · doi:10.1080/19382014.2016.1198457 · Cited by 3
Ito, K., Ookawara, S., Ishibashi, K., & Morishita, Y. (2017) · Nano Reviews & Experiments · doi:10.1080/20022727.2017.1341758 · Cited by 3
Forbes, S., Robinson, S., Parker, K. H., Macdonald, I. A., McCarthy, M. I., & Johnston, D. G. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.91 · Cited by 3
Haurigot, V., Jiménez, V., & Bosch, F. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch70 · Cited by 3
Meningioma: A Clinicopathological Correlation
Shenoy, A. S., Khade, S., & Waghmare, R. S. (2019) · Annals of Pathology and Laboratory Medicine · doi:10.21276/apalm.2354 · Cited by 2
Molecular Pathology and Therapeutic Strategies of Type 2 Diabetes
Liao, H. Z., Liang, Y., Wang, Y., & Liang, C. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230320162753 · Cited by 4
Hormonal control of diabetes type 2 after surgery: Clinical and experimental evaluation
Frezza, E. E. (2009) · Asian Journal of Endoscopic Surgery · doi:10.1111/j.1758-5910.2009.00001.x · Cited by 2
Sood, R., Kritika, Sanjay, & Lee, H. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107219 · Cited by 1
Wang, L., Guo, F., Wei, S., & Zhao, R. (2010) · Physiological Research · doi:10.33549/physiolres.931815 · Cited by 1
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2014) · Springer eBooks · doi:10.1007/978-3-319-09915-6_21 · Cited by 1
Tian, Q., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Wu, Y., Zhou, Z., Liu, S., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134328 · Cited by 1
Marchi, D., Cerepaka, C., Garman, L., & Williams, W. R. (2024) · Comparative Medicine · doi:10.30802/aalas-cm-23-000077 · Cited by 1
Molecular Basis of Liver Disease
Monga, S. P., & Behari, J. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00020-2 · Cited by 2
Newer therapeutic approaches towards the management of diabetes mellitus: an update
Lin, H.-L., SHUKRI, F. N. M., YIH, E. S., SHA, G. H., JING, G. S., Jin, G. W., HOONG, C. W., YING, C. Q., Panda, B. P., Candasamy, M., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.19.03655-3 · Cited by 1
Glucagon-like peptide-1 (GLP-1) and satiation
Rüttimann, E. B. (2010) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-006089995 · Cited by 3
GLP-1R activation is a key pathway to alleviate the metabolic disorder in L02 cellsPreprint
Tian, Q. J., Liu, Y., Liu, J., Yuan, P., Li, H., Han, X.-F., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v1 · Cited by 1
Jiménez, V., & Bosch, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch78 · Cited by 1
Athanasia, K., Marina, S., & Stavros, I. (2011) · InTech eBooks · doi:10.5772/20616
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Improving Insulin Sensitivity: A Review of New Therapies
Rhee, M. K., & Umpierrez, G. E. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60023-5 · Cited by 1
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Farah, L. X. S. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-05102015-114814
Approche multifonctionnelle mitochondriale par puce à ADN dédiée
Arvier, M. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
The role of leptin in the regulation of glucose homeostasis
Levi, J. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071042
Paulo, S., & Girardi, C. (2015)
Molecular Therapy for Type 1 and Type 2 Diabetes
Samson, S. L., Yechoor, V. K., & Chan, L. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch37
Farr, S. (2017) · TSpace (University of Toronto)
Tian, Q. J., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v2
Current literature in diabetes
(2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.812
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
González, J. G. (2011) · doi:10.24275/uami.m900nt67v · Cited by 4
Molecular Basis of Liver Disease
Monga, S. P., & Behari, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00020-1
Molecular Therapy for Type 1 and Type 2 Diabetes
Samson, S. L., Yechoor, V. K., & Chan, L. (2015) · CRC Press eBooks · doi:10.1201/b18002-44
Xu, C., Zheng, Z., Yang, K. Y., Wu, R., Cao, J., & Duan, J. (2025) · Research Square · doi:10.21203/rs.3.rs-5880424/v1
Lee, Y.-S., Seo, Y.-L., Song, G. J., Cho, K. S., Yoo, Y. K., & Cheong, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6546219/v1 · Cited by 1
Self-citationA synthetic hyperglycemia-sensing gene circuit enhances blood glucose homeostasis in diabetic mice
Zhang, Y., Deng, S., Zhu, Y., Li, X., Deng, J., Wang, C., Sun, J., Bao, F., Tang, S., Ye, H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.059 · Cited by 1
Vozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
Metadata
- Authors
- Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S.
- Affiliations
- Rosalind Franklin University of Medicine and Science (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 56
- Issue
- 6
- Pages
- 1671-1679
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2096880961
- Cited by
- 158
- References
- 50
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 7 · 2013: 7 · 2012: 12
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- glucagon-like peptide-1, gene therapy, adenoviral vector, ob/ob mice, obesity, type 2 diabetes, diabetes remission, insulin sensitivity, hepatic gluconeogenesis, insulin signaling, IRS-1, beta-cell function, glucose tolerance, insulin-stimulated glucose uptake, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, fatty acid synthase
- MeSH terms
- Animals, Diabetes Mellitus, Experimental, Gluconeogenesis, Glucose Tolerance Test, Insulin, Liver, Mice, Obese, RNA, Messenger, Genetic Therapy, Reverse Transcriptase Polymerase Chain Reaction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.